This study is in progress, not accepting new patients
A Phase 2 Study to Evaluate Safety of Long-term AL001 Dosing in Frontotemporal Dementia (FTD) Patients (INFRONT-2)
Summary
- Eligibility
- for people ages 18-85 (full criteria)
- Location
- at San Francisco, California and other locations
- Dates
- study startedestimated completion
- Principal Investigator
- by Peter Ljubenkov
Description
Summary
Official Title
Details
Keywords
Eligibility
Locations
Lead Scientist at UCSF
- Peter Ljubenkov
Assistant Professor, Neurology, School of Medicine. Authored (or co-authored) 36 research publications
Details
- Status
- in progress, not accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Alector Inc.
- ID
- NCT03987295
- Phase
- Phase 2 research study
- Study Type
- Interventional
- Participants
- Expecting 40 study participants
- Last Updated